Literature DB >> 98585

Antibody-dependent lymphocytotoxicity: an analysis of effector cell-target cell interactions.

M H van Oers, R E de Goede, W P Zeijlemaker.   

Abstract

Antibody-dependent lymphocytotoxicity (ADL) was studied with human peripheral blood lymphocytes as effector cells and P815 mouse mastocytoma cells, sensitized with rabbit IgG antibodies, as target cells. Enzyme-substrate-like kinetics were used to describe ADL inhibition induced by two types of inhibitors. Human IgG, both native and heat-aggregated, proved to be a competitive inhibitor of ADL at the target cell level. Human peripheral blood monocytes inhibited ADL in an apparently irreversible fashion, without appreciable evidence for competition. The data obtained provide strong support for the validity of an enzyme-substrate-like mechanism of ADL. Moreover, our results indicate that in order to measure the lytic capacity properly, cell populations, well defined as to their composition, should be used. In the second part of the study, it was investigated whether the two types of cells capable of lysing sensitized target cells, i.e., null cells and T cells, differed with respect to their affinity for the target cells. Application of enzyme-like kinetics revealed considerable differences in maximal killing rate between the two subsets of K cells. However, the parameter related to the affinity toward the target cells was found to be of the same magnitude for the two types of effector cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 98585

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Macrophage-alloantibody-target cell interactions. III. Stripping of antibody-coated cells by human macrophages.

Authors:  P F Halloran; M Stubbs
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

2.  Interactions between soluble IgG, complement and cells in lymphocyte and monocyte ADCC.

Authors:  R N Poston; R S Morgan
Journal:  Immunology       Date:  1983-11       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.